Skip to main content

CORRECTION article

Front. Immunol., 20 November 2018
Sec. T Cell Biology
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.02606

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

This article is a correction to:

  1. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

    1. Read original article
\r\nLisa A. KingLisa A. King1Roeland LamerisRoeland Lameris1Tanja D. de GruijlTanja D. de Gruijl1Hans J. van der Vliet,*Hans J. van der Vliet1,2*
  • 1Department of Medical Oncology, VU University Medical Center and Cancer Center Amsterdam, Amsterdam, Netherlands
  • 2Lava Therapeutics, Den Bosch, Netherlands

A Corrigendum on
CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond

by King, L. A., Lameris, R., de Gruijl, T. D., and van der Vliet, H. J. (2018). Front. Immunol. 9:1519. doi: 10.3389/fimmu.2018.01519

In the original article, we neglected to disclose that authors Lisa A. King and Roeland Lameris are currently funded by Lava Therapeutics and that Hans J. van der Vliet also acts as chief scientific officer of Lava Therapeutics. Hans J. van der Vliet's affiliation has been updated to reflect this. The corrected Conflict of Interest statement appears below.

Conflict of Interest Statement

LK and Rl are funded by Lava Therapeutics. HV acts as chief scientific officer of Lava Therapeutics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Conflict of Interest Statement

LK and Rl are funded by Lava Therapeutics. HV acts as chief scientific officer of Lava Therapeutics.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: iNKT cells, CD1d, α-GalCer, glycolipids, cancer immunotherapy

Citation: King LA, Lameris R, de Gruijl TD and van der Vliet HJ (2018) Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond. Front. Immunol. 9:2606. doi: 10.3389/fimmu.2018.02606

Received: 19 October 2018; Accepted: 23 October 2018;
Published: 20 November 2018.

Approved by:

Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2018 King, Lameris, de Gruijl and van der Vliet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hans J. van der Vliet, jj.vandervliet@vumc.nl

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.